Dendreon Cancer Drug Approved

NEW YORK, (GaeaTimes.com)- Provenge which happens to be a cancer vaccine from Dendreon Corp has finally emerged a winner thus putting an end to the legal battle against the American regulators which has been into existence for three long years. What’s rewarding in this case is Dendreon becoming the very first one to launch a cancer vaccine successfully which shall be effective in killing the tumors by employing the human immune system.

With approval from FDA, Dendreon Provenge is said to score an annual sale amounting to $4.3 billion by the end of the year 2020. Joseph Pantginis declared in his research reports that Denderons land mark discovery is a revolution in the field of cancer immunotherapy. Dendreon Provenge is made to be used for the treatment of prostate tumors and is now undergoing a clinical trial at a primary basis. Dendreon has announced that the drug shall be made available in a large scale after the medicinal plants of the company are established by the year 2011. Reportedly, Dendreon Provenge will cost $93,000 that shall witness a three phase treatment for all cancer patients.

Dendreon had submitted the patent of the drug application before FDA way back in the year of 2006 following which a medicinal advisory board had backed the approval of the drug. Owing to the recent approval of Dendreon Provenge FDA (Food and Drug Administration) shall have to monitor all study reports comprising 1,500 patients who were treated for Provenge. Janice Reichert who happens to be a senior research associate for Tufts Center for the Study of Drug Development, Boston told the media that FDA’s approval of Dendreon Provenge shall open up new avenues of treatment for a deadly disease like cancer.